From: Immune ablation and stem-cell therapy in autoimmune disease - Clinical experience
Disease/ | Â |
---|---|
general | Â |
principles | Criteria |
General | Failed best available conventional therapy |
 | Progressive disease, poor prognosis (for life or organ) |
 | Reasonable quality of life if autoimmune disease activity |
 |    were arrested |
 | <60 years old |
 | Able to withstand HSC transplantation (especially |
 |    cyclophosphamide 4 g/m2) |
SSc | Diffuse skin disease for <3 years and progressive plus |
 |    other organ involvement |
 | Modified Rodnan >16 (max 51) |
 | Diffuse skin disease for >3 years or limited skin and vital |
 |    organ involvement (threatening) |
 | Mean PAP <50 mmHg, DLCO >45% predicted |
 | LVEF >50% of normal (on echo), >45% MUGA |
 | Controlled arrhythmias |
 | Hypertension controlled by ACE inhibitors |
 | Serum creatinine <1.5 times normal upper limit |
RA | Failed: two DMARDS (including methotrexate) + any |
 |    combination of DMARDS + anti-TNF regimen |
 | Progressive destruction |
 | Disease duration 2-10 years |
MS | Disease duration ≥ 1 year |
 | EDSS between 3.0 and 6.5 |
 | Disability progression sustained for at least 6 months |
 |    during the previous 2 years of: |
 |    ≥ 1.5 EDSS points if entry EDSS between 3.0 and 5.0 |
 |    ≥ 1.0 EDSS point if entry EDSS ≥ 5.5 |
 | Primary or secondary progressive MS |
 | Clinical or MRI activity during the past year |